Biotech firm BeiGene slides in Shanghai debut after $3.5b STAR Market IPO

Biotech firm BeiGene slides in Shanghai debut after $3.5b STAR Market IPO

Stock information is displayed on an electronic board at a securities brokerage in Shanghai, Chin. Photographer: Qilai Shen/Bloomberg

Cancer treatment specialist BeiGene Ltd plunged 16.4% on its Shanghai debut on Wednesday after raising $3.5 billion, hit by concerns over its valuation amid potential US sanctions on Chinese biotech companies.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter